ARGX vs. HLN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ARGX and HLN, comparing key factors like performance, valuation metrics, dividends, and financial strength.
Company Overview
ARGX’s market capitalization stands at 35.21 billion USD, while HLN’s is 49.91 billion USD, indicating their market valuations are broadly comparable.
HLN carries a higher beta at 0.24, indicating it’s more sensitive to market moves, while ARGX (beta: 0.04) exhibits greater stability.
ARGX and HLN are both American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies without directly engaging with overseas stock exchanges.
Symbol | ARGX | HLN |
---|---|---|
Company Name | argenx SE | Haleon plc |
Country | NL | GB |
Sector | Healthcare | Healthcare |
Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
CEO | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | Mr. Brian James McNamara |
Price | 576.64 USD | 10.98 USD |
Market Cap | 35.21 billion USD | 49.91 billion USD |
Beta | 0.04 | 0.24 |
Exchange | NASDAQ | NYSE |
IPO Date | May 18, 2017 | July 25, 2022 |
ADR | Yes | Yes |
Performance Comparison
This chart compares the performance of ARGX and HLN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
This section compares the market valuation of ARGX and HLN. Key takeaways regarding their valuation, when viewed within their industry context, are presented in the commentary that follows.
- HLN’s Forward PEG ratio of -0.25 is negative. Such a figure commonly arises from negative earnings or forecasts of diminishing profitability, making standard valuation comparisons based on growth particularly challenging.
Symbol | ARGX | HLN |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | 51.13 | 25.25 |
Forward PEG Ratio (TTM) | 1.33 | -0.25 |
Price-to-Sales Ratio (P/S, TTM) | 16.51 | 3.20 |
Price-to-Book Ratio (P/B, TTM) | 7.76 | 2.25 |
EV-to-EBITDA (TTM) | 4577.12 | 18.92 |
EV-to-Sales (TTM) | 15.86 | 3.91 |
Dividend Comparison
ARGX currently offers no dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while HLN provides a 1.65% dividend yield, offering investors a component of income return.
Symbol | ARGX | HLN |
---|---|---|
Dividend Yield (TTM) | 0.00% | 1.65% |
Financial Strength Metrics Comparison
This section evaluates the financial strength of ARGX and HLN. Noteworthy observations on their financial resilience, considered from an industry perspective, are detailed in the points that follow.
- HLN’s current ratio of 0.98 falls into the low category. This can indicate potential stress on the company's ability to address its short-term liabilities, suggesting that its liquid assets may not provide a strong safety margin over its immediate financial commitments, possibly impacting its operational flexibility.
- ARGX’s Interest Coverage Ratio (ICR) of -20.85 is negative. This implies its operating earnings are insufficient to meet its interest expenses, a serious situation that threatens its financial stability and capacity to honor debt commitments.
Symbol | ARGX | HLN |
---|---|---|
Current Ratio (TTM) | 7.29 | 0.98 |
Quick Ratio (TTM) | 6.68 | 0.78 |
Debt-to-Equity Ratio (TTM) | 0.01 | 0.62 |
Debt-to-Asset Ratio (TTM) | 0.01 | 0.29 |
Net Debt-to-EBITDA Ratio (TTM) | -189.75 | 3.41 |
Interest Coverage Ratio (TTM) | -20.85 | 5.60 |